Hosted on MSN
With a New Take on an Old Schizophrenia Drug, LB Pharma Prepares IPO to Fund Phase 3 Test
Many drugs are available for schizophrenia, but insufficient efficacy and intolerable side effects leave an unmet need that biotech companies are still trying to fill. LB Pharmaceuticals is not ...
Key Points Interested in Maplight Therapeutics, Inc.? Here are five stocks we like better. ML-007C-MA met the Phase II ...
As Teva proceeds down the more muted growth path that it telegraphed early this year, the generics and innovative medicines ...
Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities ...
Medincell (Euronext Paris: MEDCL) partner, Teva Pharmaceuticals (NYSE and TASE: TEVA), announced today that UZEDY® U.S. net sales reached a record $77 million in Q2 2026, up 43% year-on-year. Teva ...
Hello everybody, and welcome to the Q2 2026 Teva Pharmaceutical Industries Earnings Conference Call. My name is Elliot. I'll be coordinating your call today. [Operator Instructions] I would now like ...
Detailed price information for Cspc Pharm Group Ltd Ord (CHJTF) from The Globe and Mail including charting and trades.
At a May MAHA Institute summit organized around the theme of “overmedicalization,” the health secretary announced an action ...
What began as a dream decades ago grew into a sweeping tale of Guardians, knights, shamans, living stars, and a threat ...
A multibillion-dollar investment in synthetic 5-MeO-DMT underscores growing optimism about its antidepressant potential.
The International Society for Psychological and Social Approaches to Psychiatry just celebrated its 70th birthday in Lausanne ...
Alix Earle shared she had a panic attack before taking a brief break from social media, opening up about how “there was a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results